re: Ann: Landmark OEM agreement with leading ... Before today,...

re: Ann: Landmark OEM agreement with leading ... Before today, market cap was around $4,000,000

But the writing was on the wall for those who had researched.

Here is what was in last November's company update:

Q1 EBITDA of $221,000 versus budget of $44,000
? Record first quarter sales of $2.4 million ? ahead of budget
? Result does not include contribution from Medivet sales ? expected Q2
? Revenue and EBITDA margin growth expected to continue

Sydney, Australia: Medical products manufacturer and distributor Medical Australia Limited (ASX: MLA)
today reported record sales and EBITDA for the first quarter of Financial Year 2011.

Sales were $2.4 million, a $663,000 improvement on the immediate past quarter and a record performance for the company.

Revenue in September alone was $852,000.

EBITDA was $221,000 excluding one-off non-operating, non-recurring expenses of $51,000, with the
company achieving profitability for every month in the quarter.

EBITDA performance was against a forecast
of $44,000 for the first quarter.

The EBITDA/sales margin of almost 10 per cent reflects the progress MLA has made in reducing its cost base and strengthening its global supply chain.

The result only includes a small contribution from the company?s supply and manufacturing agreement
with Medivet (as reported to the market 12 July 2010).

Revenue from the Medivet partnership is expected
to ramp up significantly from the second quarter as sales from distribution agreements recently reached by
Medivet in seven new countries start to come on stream.